Results 241 to 250 of about 2,530,199 (377)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors

HYPERTENSION, 2004
Y. Ishiyama, P. Gallagher, D. Averill, E. Tallant, K. Brosnihan, C. Ferrario   +5 more
semanticscholar   +1 more source

Aprocitentan in hypertension management: clinical efficacy, safety, and future prospects. [PDF]

Ann Med Surg (Lond)
Riaz R, Ahmed U, Naqi U, Afaq L, Shaukat A, Khan Y, Akilimali A.   +6 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle

Circulation, 2003
Chao-Hung Wang, Shu-hong Li, R. Weisel, P. Fedak, A. Dumont, P. Szmitko, Ren-Ke Li, Donald A. G. Mickle, S. Verma   +8 more
semanticscholar   +1 more source

New Therapies for the Management of Chronic Kidney Disease. [PDF]

Cureus
Treihaft AM, Parikh MA, Jackson KA, Frishman WH, Peterson SJ.   +4 more
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Impact of perinatal hypertonic NaCl access on adult offspring's sodium intake and angiotensin and vasopressin systems under hypertension model. [PDF]

Sci Rep
Porcari CY, Lencina CA, Amigone JL, Antunes-Rodrigues J, Caeiro XE, Godino A.   +5 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Editorial: Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches. [PDF]

Front Pharmacol
Srivastava SP, Kanasaki K.
europepmc   +1 more source